Sarah Park
Chief Administrative Officer at Arkuda Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gerhard Koenig | M | 63 |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | 6 years |
Duane Burnett | M | - |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | 6 years |
Robert Urban | M | - |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | - |
Pascale Witz | F | 57 |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | - |
Henry Skinner | M | 60 |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | - |
Bruce Booth | M | 49 |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | - |
Raymond Hurst | M | - |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | 4 years |
Christopher O’Donnell | M | 55 |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | - |
Ming Cheah | M | - |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | 2 years |
Irena Webster | F | - |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | 1 years |
Raymond Kelleher | M | 59 |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 11 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sarah Park
- Personal Network